Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alaunos Therapeutics, Inc. (TCRT : NSDQ)

• Company Description    Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $3.23 Daily Weekly Monthly 20 Day Moving Average: 54,713 shares Shares Outstanding: 2.32 (millions) Market Capitalization: $7.50 (millions) Beta: -1.28 52 Week High: $6.20 52 Week Low: $1.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.03% -9.88% 12 Week -19.05% -20.35% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 501 E LAS OLAS BLVD SUITE 300 - FORT LAUDERDALE,FL 33301 USA ph: 346-355-4099 fax: 617-241-2855 ir@alaunos.com http://www.alaunos.com

• General Corporate Information    Officers Dale Curtis Hogue - Interim Chief Executive Officer Ferdinand Groenewald - Vice President Robert Hofmeister - Director Robert W. Postma - Director Jaime Vieser - Director Peer Information Alaunos Therapeutics, Inc. (GSAC) Alaunos Therapeutics, Inc. (CASI) Alaunos Therapeutics, Inc. (ALCD.) Alaunos Therapeutics, Inc. (OMNN) Alaunos Therapeutics, Inc. (CGPI.) Alaunos Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98973P309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/30/26 Share - Related Items Shares Outstanding: 2.32 Most Recent Split Date: 7.00 (0.10:1) Beta: -1.28 Market Capitalization: $7.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.68 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 21.43% vs. Previous Quarter: 12.70% Sales Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -50.00% ROE 12/31/25 - - 09/30/25 - -167.97 06/30/25 - -168.02 ROA 12/31/25 - - 09/30/25 - -120.74 06/30/25 - -121.37 Current Ratio 12/31/25 - - 09/30/25 - 2.92 06/30/25 - 3.48 Quick Ratio 12/31/25 - - 09/30/25 - 2.92 06/30/25 - 3.48 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -67,066.66 06/30/25 - -66,533.33 Book Value 12/31/25 - - 09/30/25 - 1.21 06/30/25 - 2.23 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©